About 20 results found for searched term "Sphingosine-1-phosphate" (0.126 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M7319 | Sphingosine-1-phosphate | S1P Receptor |
| S1P | ||
| Sphingosine-1-phosphate (S1P) is an agonist of S1P1-5 receptors and a ligand of GPR3, GPR6 and GPR12. Sphingosine-1-phosphate is an intracellular second messenger and mobilizes Ca2+ as an extracellular ligand for G protein-coupled receptors. | ||
| M5244 | Ozanimod | S1P Receptor |
| RPC1063 | ||
| Ozanimod (RPC1063) is a selective, orally active sphingosine-1-phosphate (S1P) receptor modulator that binds to S1PR1 and S1PR5, and can be used in studies related to ulcerative colitis (UC). | ||
| M5886 | Ponesimod | S1P Receptor |
| ACT-128800 | ||
| Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator with EC50 of 5.7 nM. | ||
| M7560 | Cenerimod | S1P Receptor |
| ACT-334441 | ||
| Cenerimod (ACT-334441) is a potentially first-in-class (first-in-class), potent, highly selective, orally active sphingosine 1-phosphate 1 (S1P1) receptor agonist with an EC50 value of 2.7 nM for use in studies related to systemic lupus erythematosus (SLE). | ||
| M7570 | Amiselimod hydrochloride | S1P Receptor |
| MT-1303 hydrochloride | ||
| Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators. | ||
| M8431 | CYM50358 | S1P Receptor |
| CYM50358 is a potent, selective antagonist of the sphingosine-1-phosphate receptor 4 (S1P4). | ||
| M8646 | A-971432 | S1P Receptor |
| A-971432 is an orally bioavailable, non-clastogenic, azetidinecarboxylate compound that acts as a highly potent and selective sphingosine-1-phosphate receptor 5 agonist (IC50 = 6 nM/S1P5, 362 nM/S1P1 and >10 μM/S1P3 in a radio-ligand binding assay). | ||
| M8784 | NIBR-0213 | S1P Receptor |
| NIBR-0213 is an orally active, potent and S1P1-selective sphingosine 1-phosphate (S1P) receptor antagonist. | ||
| M10226 | Etrasimod (APD334) | S1P Receptor |
| APD-334 | ||
| Etrasimod (APD334) is a specific and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor, with IC50 of 1.88 nM in CHO cells. | ||
| M13998 | ASP-4058 | S1P Receptor |
| ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. | ||
| M14000 | Fingolimod | S1P Receptor |
| FTY720 free base | ||
| Fingolimod (FTY720 free base) is a sphingosine 1-phosphate (S1P) antagonist with an IC50 of 0.033 nM in K562 and NK cells. Fingolimod also is a pak1 activator, a immunosuppressant. | ||
| M21034 | SKI-V | SPHK |
| SKI V is a noncompetitive and potent inhibitor of non-lipid sphingosine kinase with IC50 of 2 μM for GST-hSK. SKI-V also inhibits PI3K with IC50 of 6 μM for hPI3k. SKI-V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P) and induces apoptosis with antitumor activity. | ||
| M28004 | Siponimod hemifumarate | LPL Receptor |
| BAF-312 hemifumarate | ||
| Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC50s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research. | ||
| M28144 | RP101075 | S1P Receptor |
| RP101075, an active metabolite of Ozanimod, is a potent, orally active S1PR (sphingosine-1-phosphate receptor 1) agonist, with an EC50 of 0.27 nM. RP101075 displays >100-fold selectivity over S1PR5 (EC50=5.9 nM) and >10000-fold over S1PR 2, 3, and 4. RP101075 displays superior cardiovascular safety profile. | ||
| M28232 | CYM50179 | LPL Receptor |
| CYM50179 (compound 22n) is a potent and selective S1P4-R (Sphingosine-1-phosphate4 receptor) agonist with an EC50 of 46 nM. | ||
| M28696 | Ozanimod hydrochloride | S1P Receptor |
| RPC-1063 hydrochloride | ||
| Ozanimod (RPC-1063) hydrochloride, a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity selectively to S1P receptor subtypes 1 (S1P1) and 5 (S1P5). Ozanimod hydrochloride has modulate effect for hS1P1 and hS1P5 receptor with EC50s of 1.03 nM and 8.6 nM, respectively. Ozanimod hydrochloride can be used for the research of relapsing multiple sclerosis (MS) . | ||
| M29002 | SLM6031434 hydrochloride | SPHK |
| SLM6031434 hydrochloride is a highly selective sphingosine kinase 2 (SphK2) inhibitor with Kis of 0.4 μM, 0.5 μM, >20 μM, 22 μM for mSphK2, rSphK2, mSphK1 and rSphK1, respectively. SLM6031434 hydrochloride decrease Sphingosine 1-phosphate (S1P) levels in U937 monocytic leukemia cells. SLM6031434 hydrochloride has the potential for renal fibrosis research. | ||
| M29857 | CAY10444 | LPL Receptor |
| BML-241 | ||
| CAY10444 (BML-241) is a sphingosine-1-phosphate 3 (S1P3) antagonist. CAY10444 inhibits by 37% S1P-induced increases in Ca2+ in HeLa cells expressing S1P3 receptors. | ||
| M30823 | Ceralifimod | LPL Receptor |
| ONO-4641 | ||
| Ceralifimod (ONO-4641) is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC50s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively. | ||
| M39090 | Sphinganine 1-phosphate | Metabolite/Endogenous Metabolite |
| Sphinganine 1-phosphate (D-erythro-Dihydrosphingosine 1-phosphate) is a polar sphingolipid metabolite that regulates cell migration, differentiation, survival and complex physiological processes. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
